NCT05085197View on ClinicalTrials.gov

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

April 5, 2022

Study Completion Date

April 5, 2022

Conditions
Healthy
Interventions
DRUG

STSA-1005 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1005 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1005 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1005 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Trial Locations (1)

66212

AltaSciences Clinical Kansas, Inc, Overland Park

All Listed Sponsors
lead

Staidson Biopharma Inc.

INDUSTRY

NCT05085197 - The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects | Biotech Hunter | Biotech Hunter